Overview
Who’s On The Tightrope? Understanding Patients With Chronic Polyvascular Disease
The Expert Circle
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Many atherosclerotic cardiovascular disease (ASCVD) patients do well after suffering a heart attack or stroke, but frequently, these patients continue to be at high risk for recurrent cardiovascular events and are not necessarily stable. It is important to understand the patients, particularly those with polyvascular disease, at higher risk for recurrent events. Are you current with how to best manage these patients? Find out in this short vlog, where Dr. Christian Ruff from Brigham and Women's and Harvard Medical School, discusses the COMPASS trial and its implications for patients with stably unstable polyvascular disease.
This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, and primary care physicians.
The purpose of this activity is to provide learners with an engaging, concise presentation to help them optimize anticoagulant therapy in their patients with polyvascular disease. Learners post-activity will also be better able to interpret the latest data on DOACs as for patients with stably unstable ASCVD.
Upon completion of this activity, participants will be able to:
• Identify stably unstable patients with chronic ASCVD that are at increased risk for recurrent events and complications
• Outline the potential risks and complications of patients with polyvascular disease in comparison with those patients with only CAD
• Compare and contrast treatment strategies for patients with CAD and PAD
• Identify stably unstable patients with chronic ASCVD that are at increased risk for recurrent events and complications
• Outline the potential risks and complications of patients with polyvascular disease in comparison with those patients with only CAD
• Compare and contrast treatment strategies for patients with CAD and PAD
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
This activity was part of a serial learning curriculum. This functionality is no longer available due to activity expiration.
Christian Ruff, MD, MPH
Director, General Cardiology, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor
Harvard Medical School
Boston, MA
Director, General Cardiology, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor
Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Christian Ruff, MD, MPH
Consultant (Occasional): Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Portola
Grant/Research Support recipient: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
